scholarly journals Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study

2005 ◽  
Vol 20 (6) ◽  
pp. 966 ◽  
Author(s):  
Jin Ho Baek ◽  
Jong Gwang Kim ◽  
Sang Kyun Sohn ◽  
Dong Hwan Kim ◽  
Kyu Bo Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Multicenter Phase ◽  
Pretreated Patients ◽  
Line Chemotherapy

scholarly journals Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy

Oncotarget ◽  
2017 ◽  
Vol 8 (61) ◽  
pp. 104552-104559 ◽  
Author(s):  
Hanguang Ruan ◽  
Junlin Dong ◽  
Xueliang Zhou ◽  
Juan Xiong ◽  
Hua Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Gastric Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Multicenter Phase ◽  
Line Chemotherapy

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

2012 ◽  
Vol 69 (6) ◽  
pp. 1641-1645 ◽  
Author(s):  
Alberto Zaniboni ◽  
Enrico Aitini ◽  
Sandro Barni ◽  
Daris Ferrari ◽  
Stefano Cascinu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Pancreatic Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Multicenter Phase ◽  
Line Chemotherapy

Second-line chemotherapy with mitomycin C and S-1 in patients with advanced gastric cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14083-14083 ◽  
Author(s):  
D. Shin ◽  
S. Lee ◽  
S. Park ◽  
S. Bang ◽  
E. Cho ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Single Agent ◽  
Objective Response ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Previously Treated ◽  
Line Chemotherapy

14083 Background: S-1, a fourth generation oral fluoropyrimidine that mimics infusional 5-fluorouracil, has demonstrated activity against advanced gastric cancer. Based on a single agent activity and in vitro synergy between mitomycin C (MMC) and 5-fluorouracil, we conducted a phase II study to assess the efficacy and tolerability of the combination of S-1 and MMC as second-line chemotherapy for previously treated, advanced gastric cancer. Methods: Patients with measurable gastric cancer, progressive after at least one prior chemotherapy for metastatic disease, were treated with MMC 7 mg/m2 on day 1 and S-1 40 mg/m2 twice daily as an intermittent regimen of 4 weeks of treatment followed by a 2-week rest. Treatment was repeated every 6 weeks, for up to 4 cycles. Objective response rate was the primary endpoint and was evaluated every 2 cycles of chemotherapy. With a single-stage phase II design, at least 25 patients were required. Results: Of the 26 patients registered, 24 patients were evaluable for response and 26 for safety. Eighteen patients (69%) were previously treated with 5-fluorouracil-based chemotherapy, and 10 (39%) were treated with taxanes. The patients’ median age was 55 years (range, 38–73) and 7 (27%) had an ECOG performance status of 2. A total of 64 chemotherapy cycles were delivered (median, 2; range, 1–4). In an intent-to-treat analysis, 6 patients (23%) achieved a partial response, which maintained for 3.5 months. The median progression-free and overall survivals were 4.4 months (95% CI, 1.7–7.2) and 5.4 months (95% CI, 3.4–7.4), respectively. Major toxic effects included stomatitis, diarrhea and fatigue, but were generally mild and manageable. No patient developed hemolytic reaction. Conclusions: Second-line chemotherapy with MMC and S-1 is an effective regimen for advanced gastric cancer with an acceptable toxicity profile and a convenient administration schedule. No significant financial relationships to disclose.

scholarly journals Nab-paclitaxel as second line treatment in advanced gastric cancer: A HORG multicenter phase II study

2016 ◽  
Vol 27 ◽  
pp. vi221
Author(s):  
P. Katsaounis ◽  
N. Kentepozidis ◽  
A. Kotsakis ◽  
A. Polyzos ◽  
L. Vamvakas ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
Second Line ◽  
Multicenter Phase
Sign in / Sign up

Export Citation Format

Share Document